Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamadermatol.2022.5146 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tongue necrosis secondary to giant cell arteritis, successfully treated with tocilizumab: a case report.
BMC Musculoskelet Disord
May 2023
Department of Rheumatology, Northwell Health, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Long Island, NY, USA.
Background: Giant Cell Arteritis (GCA) is a large vessel vasculitis that most commonly presents with headache, scalp tenderness, jaw claudication, and vision changes. Various other, less common, manifestations have been reported in the literature such as scalp and tongue necrosis. Though most patients respond to corticosteroids, some cases of GCA are refractory to the high doses of corticosteroids.
View Article and Find Full Text PDFTocilizumab for Corticosteroid-Refractory Immune Checkpoint Inhibitor-Induced Generalized Morphea.
JAMA Dermatol
January 2023
Dermatology Department, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.
Long-term outcomes in corticosteroid-refractory Graves' orbitopathy treated with tocilizumab.
Clin Endocrinol (Oxf)
September 2022
Division of Immunology and Allergy, Department of Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland.
Background: Up to 20% of patients with moderate to severe Graves' orbitopathy (GO) do not respond to high-dose glucocorticoids (GC). A few studies, including a randomized trial, have demonstrated the efficacy of interleukin-6 (IL-6) blockade with tocilizumab (TCZ) in GC-refractory GO. However, data on predictors of response to TCZ and long-term outcomes are lacking.
View Article and Find Full Text PDFTocilizumab as an alternative for corticosteroid-refractory orbital myositis.
J Neuroimmunol
July 2021
Department of Neurology, Hospital Mútua Terrassa, Spain.
Tocilizumab as salvage treatment of refractory pulmonary acute graft-versus-host disease.
J Oncol Pharm Pract
April 2021
Pharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Article Synopsis
- Acute graft-versus-host disease (aGVHD) is a serious problem that can happen after bone transplant when the body fights against the new cells.
- Steroids are usually the first treatment, but some patients don’t respond well to them.
- In one case, doctors used a medicine called tocilizumab, and it helped the patient get better very quickly, showing it could be a good option for people who don’t improve with steroids.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!